Efficacy of probiotic treatment with <i>Bifidobacterium longum 536</i> for induction of remission in active ulcerative colitis: A randomized, double‐blinded, placebo‐controlled multicenter trial

Tamaki, Hiroyuki; Nakase, Hiroshi; Inoue, Satoko; Kawanami, Chiharu; Itani, Toshinao; Ohana, Masaya; Kusaka, Toshihiro; Uose, Suguru; Hisatsune, Hiroshi; Tojo, Masahiro; Noda, Teruyo; Arasawa, Souichi; Izuta, Masako; Kubo, Atsushi; Ogawa, Chikara; Matsunaka, Toshihiro; Shibatouge, Mitsushige

doi:10.1111/den.12553

Cited by 167 publications

(108 citation statements)

References 21 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…[16][17][18][19][20][21][22][23][24][25][44][45][46][47][48][49][50][51][52][53][54][55] Agreement between reviewers for assessment of trial eligibility was excellent (Kappa statistic=0.94). There were eight trials studying the efficacy of probiotics in inducing remission in active UC, 16,18,25,[44][45][46][47][48] six studying their efficacy in preventing relapse of quiescent UC, 17,19,23,[49][50][51] two studying the efficacy of probiotics in inducing remission in active CD, 52,53 two studying their efficacy in preventing relapse of quiescent CD, 24,55 and four studying their efficacy in preventing relapse of CD in remission following a surgical resection. [20][21][22]54 None of the RCTs were cross-over trials.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Systematic review with meta‐analysis: the efficacy of probiotics in inflammatory bowel disease

Derwa

Gracie

Hamlin

et al. 2017

Aliment Pharmacol Ther

296

217

View full text Add to dashboard Cite

Summary Background Ulcerative colitis (UC) and Crohn's disease (CD) are inflammatory bowel diseases (IBD). Evidence implicates disturbances of the gastrointestinal microbiota in their pathogenesis. Aim To perform a systematic review and meta‐analysis to examine the efficacy of probiotics in IBD. Methods MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched (until November 2016). Eligible randomised controlled trials (RCTs) recruited adults with UC or CD, and compared probiotics with 5‐aminosalicylates (5‐ASAs) or placebo. Dichotomous symptom data were pooled to obtain a relative risk (RR) of failure to achieve remission in active IBD, or RR of relapse of disease activity in quiescent IBD, with 95% confidence intervals (CIs). Results The search identified 12 253 citations. Twenty‐two RCTs were eligible. There was no benefit of probiotics over placebo in inducing remission in active UC (RR of failure to achieve remission=0.86; 95% CI=0.68‐1.08). However, when only trials of VSL#3 were considered there appeared to be a benefit (RR=0.74; 95% CI=0.63‐0.87). Probiotics appeared equivalent to 5‐ASAs in preventing UC relapse (RR=1.02; 95% CI=0.85‐1.23). There was no benefit of probiotics in inducing remission of active CD, in preventing relapse of quiescent CD, or in preventing relapse of CD after surgically induced remission. Conclusions VSL#3 may be effective in inducing remission in active UC. Probiotics may be as effective as 5‐ASAs in preventing relapse of quiescent UC. The efficacy of probiotics in CD remains uncertain, and more evidence from RCTs is required before their utility is known.

show abstract

Section: Resultsmentioning

confidence: 99%

“…One of the eight eligible trials compared probiotics with 5-ASAs for induction of remission of active UC, 44 and the other seven trials were placebo-controlled. 16,18,25,[45][46][47][48] Two trials were at low risk of bias. 25 Detailed study characteristics are provided in Figure 1).…”

Section: Efficacy Of Probiotics In Inducing Remission In Active Ucmentioning

confidence: 98%

Systematic review with meta‐analysis: the efficacy of probiotics in inflammatory bowel disease

Derwa

Gracie

Hamlin

et al. 2017

Aliment Pharmacol Ther

296

217

View full text Add to dashboard Cite

show abstract

“…Recently, probiotic therapy has been demonstrated to be potentially effective and safe in patients with UC. Tamaki et al, 2016 investigated the efficacy and safety of probiotic treatment with B. longum 536, which is a probiotic isolated in 1969 from the feces of a breast-fed infant, in Japanese patients with active UC using an RCT [62]. The probiotic improved clinical symptoms, such as the UC disease activity index and Rachmilewitz endoscopic index, in patients with mild to moderately active UC, but further studies are needed to clarify the efficacy and safety of B. longum 536 for UC [62].…”

Section: Resultsmentioning

confidence: 99%

Evidence of the Anti-Inflammatory Effects of Probiotics and Synbiotics in Intestinal Chronic Diseases

et al. 2017

View full text Add to dashboard Cite

Probiotics and synbiotics are used to treat chronic diseases, principally due to their role in immune system modulation and the anti-inflammatory response. The present study reviewed the effects of probiotics and synbiotics on intestinal chronic diseases in in vitro, animal, and human studies, particularly in randomized clinical trials. The selected probiotics exhibit in vitro anti-inflammatory properties. Probiotic strains and cell-free supernatants reduced the expression of pro-inflammatory cytokines via action that is principally mediated by toll-like receptors. Probiotic administration improved the clinical symptoms, histological alterations, and mucus production in most of the evaluated animal studies, but some results suggest that caution should be taken when administering these agents in the relapse stages of IBD. In addition, no effects on chronic enteropathies were reported. Probiotic supplementation appears to be potentially well tolerated, effective, and safe in patients with IBD, in both CD and UC. Indeed, probiotics such as Bifidobacterium longum 536 improved the clinical symptoms in patients with mild to moderate active UC. Although it has been proposed that probiotics can provide benefits in certain conditions, the risks and benefits should be carefully assessed before initiating any therapy in patients with IBD. For this reason, further studies are required to understand the precise mechanism by which probiotics and synbiotics affect these diseases.

show abstract

“…More recently, a trial where patients with mild-to-moderate UC (UCDAI 3-9) were supplemented with B. longum subsp. longum 536 resulted in a significant decrease in disease activity following 8-week supplementation, whereas a significant decrease was not seen in the placebo group [84]. Taken together, these trials suggest that bifidobacteria may be a promising therapy for the treatment of IBD; however, the limitations of the studies must be considered.…”

Section: Key Questionsmentioning

confidence: 93%

Exploring the role of the microbiota member Bifidobacterium in modulating immune-linked diseases

O’Neill

Schofield

Hall

2017

Emerging Topics in Life Sciences

View full text Add to dashboard Cite

The gut-associated microbiota is essential for multiple physiological processes, including immune development. Acquisition of our initial pioneer microbial communities, including the dominant early life genus Bifidobacterium, occurs at a critical period of immune maturation and programming. Bifidobacteria are resident microbiota members throughout our lifetime and have been shown to modulate specific immune cells and pathways. Notably, reductions in this genus have been associated with several diseases, including inflammatory bowel disease. In this review, we provide an overview of bifidobacteria profiles throughout life and how different strains of bifidobacteria have been implicated in immune modulation in disease states. The focus will be examining preclinical models and outcomes from clinical trials on immune-linked chronic conditions. Finally, we highlight some of the important unresolved questions in relation to Bifidobacterium-mediated immune modulation and implications for future directions, trials, and development of new therapies.

show abstract

Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double‐blinded, placebo‐controlled multicenter trial

Abstract: Supplementation with BB536 was well tolerated and reduced UCDAI scores, EI and Mayo subscores after 8 weeks in Japanese patients with mild to moderately active UC.

Cited by 167 publications

References 21 publications

Systematic review with meta‐analysis: the efficacy of probiotics in inflammatory bowel disease

Systematic review with meta‐analysis: the efficacy of probiotics in inflammatory bowel disease

Evidence of the Anti-Inflammatory Effects of Probiotics and Synbiotics in Intestinal Chronic Diseases

Exploring the role of the microbiota member Bifidobacterium in modulating immune-linked diseases

Contact Info

Product

Resources

About